The [US Fabry Disease Market] is characterized by its routes of administration, with intravenous (IV) infusion currently representing the largest segment. This dominance is due to the widespread use of enzyme replacement therapies (ERTs) like Fabrazyme and Replagal, which require biweekly IV infusions in a clinical or home setting . However, the market is witnessing a significant shift, with oral therapies rapidly emerging as the fastest-growing segment. This growth is fueled by a strong patient preference for convenient, less burdensome treatment options that can significantly improve quality of life.

The Dominance of Intravenous Administration

Intravenous administration's leadership in the US Fabry disease market is a direct consequence of the ERT standard of care. For over two decades, IV infusions have been the only life-sustaining treatment for most patients, establishing a familiar and trusted, albeit demanding, routine . The clinical infrastructure for administering IV therapies is well-established in the US, supported by specialty pharmacies and home infusion services, ensuring its continued dominance.

The Rapid Rise of Oral Therapies

Oral therapies are emerging as the fastest-growing administration route in the US Fabry disease market. The approval of Galafold (migalastat), an oral chaperone therapy for patients with amenable mutations, marked a pivotal moment, offering a convenient alternative to IV infusions . The pipeline is rich with other oral candidates, most notably venglustat, a substrate reduction therapy, which is in late-stage trials and could further revolutionize treatment by offering an oral option for a broader patient population . The convenience of oral administration, which eliminates the need for regular clinic or home infusion visits, is a key driver for this segment's rapid expansion.

The Role of Home Infusion

While IV therapy is dominant, a significant portion of it is shifting to the home setting. Home infusion services provide patients with the convenience and comfort of receiving their ERT infusions at home, reducing the burden of travel and clinic visits.

The Future of Administration Route Dynamics

Looking ahead, the [US Fabry Disease Market] will likely see a continued, though gradual, shift in administration route preferences. IV therapy will maintain its dominant position as the standard for ERT delivery. However, the oral segment is projected to experience significant growth, capturing an increasing share of the market as new oral therapies like venglustat gain approval and become available to a wider patient population. The oral therapies will become a key driver of market expansion, reflecting the strong patient demand for more convenient and less invasive treatment options.